Skip to main content
SMS Pharmaceuticals Ltd logo

SMS Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · SMSPHARMA ISIN · INE812G01025 LEI · 335800XXEADQCB7GJ514 BSE.NS Manufacturing
Open in API
Filings indexed 747 across all filing types
Latest filing 2022-08-25 Regulatory Filings
Country IN India
Listing BSE.NS SMSPHARMA

About SMS Pharmaceuticals Ltd

https://smspharma.com/

SMS Pharmaceuticals Ltd specializes in the development and large-scale manufacturing of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. The organization operates multiple manufacturing units and research centers, maintaining compliance with international regulatory standards including USFDA approvals. Its core product portfolio covers therapeutic areas such as anti-ulcerants, anti-migraine agents, anti-hypertensives, and anti-retrovirals. Beyond its proprietary product line, the company provides Contract Research and Manufacturing Services (CRAMS), offering expertise in process development, chemical synthesis, and analytical validation. The company focuses on delivering high-quality chemical solutions through integrated research and development capabilities, supporting global supply chains with a commitment to technical excellence and operational efficiency.

Recent filings

Filing Released Lang Actions
Newspaper Advertisements
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the submission of newspaper publications about the transfer of shares to the Investor Education Protection Fund (IEPF) due to unpaid/unclaimed dividends for the financial year 2014-2015. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, specifically Regulations 30 and 47. The content is an announcement of a regulatory compliance action (transfer of shares to IEPF) and the publication of related newspaper advertisements. The document is short (2216 characters) and serves as an intimation or notification rather than a detailed report or financial statement. It does not contain financial data, management discussion, or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2022-08-25 English
General updates
Notice of Dividend Amount Classification · 95% confidence The document is a detailed communication from SMS Pharmaceuticals Limited to its shareholders regarding Tax Deduction at Source (TDS) on dividend payouts for the financial year 2021-22. It includes information about dividend declaration, record dates, tax rates applicable to resident and non-resident shareholders, required documentation, and procedural instructions. The document is not a financial report, earnings release, or regulatory filing per se, but rather a shareholder communication about tax treatment on dividends. It does not contain financial statements or management discussion but is an informational letter to shareholders about dividend tax deduction procedures. This type of document fits best under the category of Notice of Dividend Amount (DIV), as it relates to dividend payment details and tax implications for shareholders.
2022-08-25 English
Transcript of Analysts/Institutional Investor Meet/Con. Call
Call Transcript Classification · 100% confidence The document is a transcript of a conference call held on August 18, 2022, discussing the financial performance for the quarter ended June 30, 2022 (Q1 FY23). It includes detailed discussions by company executives about product pipelines, revenue contributions, regulatory approvals, and future outlook. The presence of a Q&A session with analysts further confirms this is a full transcript of an earnings call. The document explicitly states it is a transcript of the conference call and contains detailed financial and operational commentary typical of earnings call transcripts. Therefore, the document fits the category of a Call Transcript (CT).
2022-08-23 English
Recording of Analysts/Institutional Investor Meet/Con. Call
Call Transcript Classification · 90% confidence The document is a letter addressed to stock exchanges regarding the audio recording of an analysts/investors conference call about the company's financial results for the first quarter ended June 30, 2022. It references the conference call and provides a link to the audio recording but does not contain the transcript or detailed financial data itself. The document is short (1317 characters) and serves as an announcement of the call recording availability. According to the classification rules, such documents are classified as Call Transcript (CT) if they contain the full transcript, but this is only an announcement of the audio recording, not the transcript itself. However, since the document is about the conference call and its recording, the closest and most appropriate category is Call Transcript (CT), as it pertains directly to the conference call content. Confidence is high because the document explicitly mentions the conference call and financial results for a specific quarter.
2022-08-18 English
Record Date
Regulatory Filings
2022-08-17 English
Book Closure
Regulatory Filings
2022-08-17 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.